We are embarking on a mission to raise a total of $2 million to directly fund a clinical trial for a promising new treatment for Langerhans Cell Histiocytosis (LCH), developed by a group of leading LCH physicians and scientists at Dana Farber Cancer Institute.
LCH is a rare disorder that occurs when a child has too many of a certain type of cell called Langerhans cells. These cells normally reside in the skin and help fight infection and destroy foreign substances in the body. In LCH, extra Langerhans cells spread through the blood and build up in certain parts of the body, where they can damage tissue or form tumors. While Langerhans cells typically accumulate in bones, they can also accumulate in the skin, lymph nodes, liver, spleen, lung, or brain. Recent studies by scientists at Dana-Farber Cancer Institute have demonstrated a mutant oncogene, BRAF V600E, in more than half of LCH biopsy samples. This suggests that LCH is a type of neoplastic disease (a disease grouping that includes benign, pre-cancerous and cancerous growths). LCH is most common in young children under 10.
The Stella Hope Fund is dedicated to the development of improved therapies for children suffering from LCH. We believe finding a more effective and less toxic treatment is possible. By advancing novel treatment modalities, children diagnosed with LCH can live healthier, better lives, without fear of an unknown future. The proposed clinical study for this new LCH treatment will be conducted by Drs Barbara Degar (Medical Director, Inpatient Oncology) and Barrett Rollins (Chief Scientific Officer, Emeritus) at The Dana Farber Cancer Institute, and is expected to commence in 2023.
Your donations will make a difference.
Find out more about LCH and the devastating lifelong impact to children afflicted with LCH by clicking here.
Would you like to learn more about working with Outcome Capital or discuss your specific needs?